Get the Stockscreener App
19.44
6.11%
1.12
Seres Therapeutics Inc stock is traded at $19.44, with a volume of 167.83K.
It is up +6.11% in the last 24 hours and up +56.90% over the past month.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
See More
Previous Close:
$18.32
Open:
$18.26
24h Volume:
167.83K
Relative Volume:
1.46
Market Cap:
$170.19M
Revenue:
$123.24M
Net Income/Loss:
$136.00K
P/E Ratio:
-972.00
EPS:
-0.02
Net Cash Flow:
$-148.99M
1W Performance:
+16.48%
1M Performance:
+56.90%
6M Performance:
+20.97%
1Y Performance:
+13.02%
1-Day Range:
$18.26
$19.59
1-Week Range:
$15.79
$19.59
52-Week Range:
$6.53
$26.40
Seres Therapeutics Inc Stock (MCRB) Company Profile
Name
Seres Therapeutics Inc
Sector
Industry
Phone
617 945 9626
Address
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
19.44 | 154.87M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-24-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-21-23 | Initiated | JP Morgan | Neutral |
| Jul-23-21 | Downgrade | Goldman | Neutral → Sell |
| May-18-21 | Resumed | Goldman | Neutral |
| Mar-05-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Sep-18-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-11-20 | Upgrade | Jefferies | Hold → Buy |
| Apr-30-19 | Initiated | Jefferies | Hold |
| Oct-22-18 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-17 | Initiated | Oppenheimer | Outperform |
| Aug-04-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-01-17 | Reiterated | FBR & Co. | Outperform |
| Aug-12-16 | Reiterated | FBR Capital | Outperform |
| Aug-01-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-01-16 | Reiterated | H.C. Wainwright | Buy |
| Jul-29-16 | Resumed | H.C. Wainwright | Buy |
| Mar-30-16 | Initiated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | Guggenheim | Buy |
| Jan-25-16 | Initiated | H.C. Wainwright | Buy |
| Oct-22-15 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-22-15 | Initiated | Canaccord Genuity | Buy |
| Jul-21-15 | Initiated | Goldman | Neutral |
| Jul-21-15 | Initiated | Leerink Partners | Outperform |
View All
Seres Therapeutics Inc Stock (MCRB) Latest News
Custom strategy builders for tracking Seres Therapeutics Inc.Market Trend Review & Precise Buy Zone Tips - Newser
Statistical indicators supporting Seres Therapeutics Inc.’s strengthCEO Change & Stock Market Timing Techniques - Newser
Using fundamentals and technicals on Seres Therapeutics Inc.July 2025 Market Mood & Weekly Setup with High ROI Potential - Newser
Published on: 2025-08-19 05:10:31 - Newser
Seres Therapeutics Inc. stock momentum explainedJuly 2025 Sector Moves & Real-Time Chart Pattern Alerts - Newser
Earnings visualization tools for Seres Therapeutics Inc.Weekly Trend Report & Fast Entry High Yield Tips - Newser
How to integrate Seres Therapeutics Inc. into portfolio analysis toolsJuly 2025 Pullbacks & Capital Efficient Trade Techniques - Newser
How to track smart money flows in Seres Therapeutics Inc.Trade Analysis Summary & Scalable Portfolio Growth Ideas - Newser
Should you wait for a breakout in Seres Therapeutics Inc.2025 Analyst Calls & Trade Opportunity Analysis Reports - Newser
Is it time to cut losses on Seres Therapeutics Inc.Quarterly Profit Report & Risk Managed Investment Strategies - Newser
Historical volatility pattern of Seres Therapeutics Inc. visualizedBond Market & AI Forecasted Entry and Exit Points - Newser
Competitive Positioning of Seres Therapeutics Inc.: Is It Leading or LaggingTrade Analysis Summary & Short-Term Trading Alerts - Newser
Using data models to predict Seres Therapeutics Inc. stock movementEarnings Overview Report & Stock Market Timing Techniques - Newser
Risk adjusted return profile for Seres Therapeutics Inc. analyzedQuarterly Portfolio Report & Breakout Confirmation Trade Signals - Newser
Has Seres Therapeutics Inc. Stock Ever Crashed Historical Volatility ReviewJuly 2025 Big Picture & AI Enhanced Trading Alerts - Newser
Order flow analysis tools used on Seres Therapeutics Inc.2025 EndofYear Setup & Risk Adjusted Swing Trade Ideas - Newser
Seres (MCRB) Q2 Loss Narrows 34% - AOL.com
Seres Therapeutics Inc. Stock Performance After Earnings: Historical InsightsRisk Management & Weekly Watchlist for Consistent Profits - Newser
What moving averages say about Seres Therapeutics Inc.July 2025 Recap & Fast Entry Momentum Alerts - Newser
Published on: 2025-08-15 16:23:19 - Newser
Is Seres Therapeutics Inc. showing signs of accumulation2025 Market Sentiment & Risk Adjusted Buy and Sell Alerts - Newser
How does Seres Therapeutics Inc. score in quality rankingsEarnings Overview Summary & Fast Moving Stock Trade Plans - mustnews.co.kr
Institutional Tools Highlight Unusual Flow in Seres Therapeutics Inc.2025 Top Decliners & Accurate Entry/Exit Alerts - thegnnews.com
Should you avoid Seres Therapeutics Inc. stock right nowJuly 2025 Highlights & Long-Term Safe Investment Ideas - sundaytimes.kr
Why Seres Therapeutics Inc. stock attracts strong analyst attention2025 AllTime Highs & Daily Volume Surge Signals - Newser
Seres Therapeutics Inc. Bounces Off Moving Average SupportReal Trader Watchlist of Hot Stocks Released - metal.it
Seres Therapeutics Reports Q2 2025 Financial Results - The Globe and Mail
Seres Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
Seres Therapeutics shares fall 1.90% after-hours following Q2 2025 earnings call. - AInvest
Promising Developments and Strategic Partnerships Drive Buy Rating for Seres Therapeutics - TipRanks
Seres Therapeutics outlines global Phase II SER-155 trial with 248-patient enrollment amid partnership talks - MSN
Seres Therapeutics: Q2 Earnings Snapshot - Connecticut Post
Seres Therapeutics: Unpacking Strategic Contradictions in Partnerships and FDA Engagements - AInvest
Seres Therapeutics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:MCRB) - Seeking Alpha
Transcript : Seres Therapeutics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Sana Biotechnology shares fall 14.12% after-hours following Seres Therapeutics' board changes and clinical advancement updates. - AInvest
Seres Therapeutics, Inc. SEC 10-Q Report - TradingView
Earnings call transcript: Seres Therapeutics reports larger-than-expected Q2 loss - Investing.com Canada
Seres Therapeutics quarterly loss per share $2.27 - MarketScreener
Seres Therapeutics August 2025 slides: SER-155 shows 77% infection reduction - Investing.com
Nxera debuts an obesity pipeline; BridgeBio battles Alynam for market share - Yahoo Finance
Seres Therapeutics: A High-Conviction Biotech Buy Amid Clinical and Strategic Momentum - AInvest
Seres Therapeutics Reports Second Quarter 2025 Financial Results - GuruFocus
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - Yahoo Finance
Seres Therapeutics Inc. Stock Analysis and ForecastAchieve consistent profits with proven methods - Jammu Links News
Is Seres Therapeutics Inc. a growth stock or a value stockRapid portfolio appreciation - Jammu Links News
Seres Therapeutics Inc Stock (MCRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Seres Therapeutics Inc Stock (MCRB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DesRosier Thomas | See Remarks |
Aug 18 '25 |
Sale |
16.65 |
76 |
1,265 |
7,455 |
| Henn Matthew R | See Remarks |
Aug 18 '25 |
Sale |
16.65 |
73 |
1,215 |
4,548 |
| Young Teresa L. | See Remarks |
Aug 18 '25 |
Sale |
16.65 |
59 |
982 |
5,215 |
| Young Teresa L. | See Remarks |
May 16 '25 |
Sale |
7.28 |
63 |
459 |
5,044 |
| Shaff Eric D. | CEO and President |
May 16 '25 |
Sale |
7.28 |
220 |
1,602 |
10,102 |
| DesRosier Thomas | Chief Legal Officer and EVP |
May 15 '25 |
Sale |
7.28 |
79 |
575 |
7,287 |
| Henn Matthew R | See Remarks |
May 16 '25 |
Sale |
7.28 |
77 |
561 |
4,383 |
| Young Teresa L. | See Remarks |
Feb 18 '25 |
Sale |
0.81 |
3,338 |
2,704 |
97,536 |
| Henn Matthew R. | See Remarks |
Feb 18 '25 |
Sale |
0.81 |
3,953 |
3,204 |
84,443 |
| Shaff Eric D. | CEO and President |
Feb 18 '25 |
Sale |
0.81 |
12,726 |
10,314 |
192,039 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):